HER2 TKI · small molecule
neratinib
2 active trials across 4 of our biomarkers, targeting HER2. Not approved for any biomarker on marked.bio yet.
Also known as HKI-272, Nerlynx.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| HER2 (ERBB2) activating mutation | 2 | 6 | Phase 2 |
| EGFR exon 19 deletion / L858R | 0 | 1 | – |
| KRAS G12C | 0 | 2 | – |
| KRAS G12D | 0 | 2 | – |
Trials
2 of 8 trials shown
-
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
…ening, histologically confirmed cancers in patients with previously documented activating HER2 mutation (see Appendix A) confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certifi…
HER2 (ERBB2) activating mutationAnatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
-
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
neratinibtrastuzumab deruxtecan FDA EU
A known HER2 activating mutation
HER2 (ERBB2) activating mutationMetastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
-
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
3.Previously underwent second-generation sequencing testing with evidence of HER2 mutation, otherwise, the patient must provide sufficient tissue samples for second-generation sequ…
HER2 (ERBB2) activating mutationAdvanced Solid Tumor
-
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
neratinibDivalproex Sodium
Phase 2 - Dose Expansion Phase: One of the following advanced solid tumors that is RAS-mutated and has progressed during or after treatment with at least one approved therapy or for wh…
KRAS G12CKRAS G12DSolid Tumor, Adult
-
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
HER2 mutation confirmed by CLIA testing of tumor, and with or without prior treatment with cetuximab or…
HER2 (ERBB2) activating mutationMetastatic Colorectal Cancer
-
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
neratinibtemsirolimus
Documented somatic ErbB2 (HER2) activating mutation.
HER2 (ERBB2) activating mutationHER2-mutant Non-Small Cell Lung Cancer
-
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
neratinibfulvestranttrastuzumab
for Registration (for patients with HER2 mutation identified at an outside CLIA certified location):
HER2 (ERBB2) activating mutationBreast Neoplasms
-
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
everolimusneratinibpalbociclibtrametinib
…nib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
EGFR exon 19 deletion / L858RKRAS G12CKRAS G12DAdvanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification
No trials match these filters.